By: Paige Britt From: targetedonc.com Key Takeaways The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% compared to the standard regimen. Median progression-free survival was 40.7 months, with an overall response rate of 85.1% for T-DXd plus pertuzumab. The safety profile of …
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
By: Alexandra Gerlach From: pharmacytimes.com Key Takeaways ADCs target specific tumor antigens, enhancing therapeutic windows and efficacy, with HER2 and TROP-2 as key targets in breast cancer. HER2-targeting ADCs, T-DM1 and T-DXd, have shown significant benefits in early and metastatic breast cancer, improving survival and response rates. TROP-2-targeting ADCs, SG and Dato-DXd, are approved for metastatic breast cancer, showing efficacy …
Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer
By: Gregory Laub From: medpagetoday.com After the results of CLEOPATRA, taxane chemotherapy with dual anti-HER2-blocker therapy Herceptin [trastuzumab]/Perjeta [pertuzumab] became the standard of care for HER2-positive metastatic breast cancer. With this study, we were looking to see how many patients in the real world received that regimen as a first-line standard-of-care therapy, which we defined as “1LSOC” compared to an …
DETECT V: HER2+, HR+ Metastatic Breast Cancer can be Safely Treated Without Chemotherapy
By: Vicki Moore, PhD From: cancertherapyadvisor.com It may be possible to safely omit chemotherapy for patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer, according to an updated analysis of the DETECT V study. Wolfgang Janni, MD, PhD, of the University Hospital Ulm in Ulm, Germany presented the findings at the San Antonio Breast Cancer Symposium 2025. The randomized, multicenter, …
CAR T-Cell Therapy for HER2+ Breast Cancer With CNS Metastases
From: oncodaily.com A phase 1 clinical trial presented at the 2025 Society of Neuro-Oncology Annual Meeting reported encouraging early safety findings for intraventricular HER2-directed CAR T-cell therapy in patients with HER2-positive breast cancer who developed recurrent brain metastases or leptomeningeal metastases (LM)—two of the most devastating complications in advanced HER2-driven disease. Led by Jana Portnow, MD, from City of Hope, …
HER2-Positive Breast Cancer Diet
From: healthline.com Foods such as sugar, saturated fats, and alcohol may promote the spread of HER2-positive breast cancer and should be avoided if you have this cancer. Some other foods may slow the cancer’s progress. Can diet help HER2-positive breast cancer? Your daily diet can affect your overall health. About 18% of all cancersTrusted Source may be related to diet, …
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
By: Roman Fabbricatore From: .cancernetwork.com The FDA has granted fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) breakthrough therapy designation as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, according to a news release from the drug’s developer, Daiichi-Sankyo.1 Based on results from the phase 3 DESTINY-Breast09 trial (NCT04784715), the agency’s decision follows data presented during a late-breaking oral …
FDA Grants Breakthrough Therapy Designation to Frontline T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer
By: Chris Ryan From: onclive.com he FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab for the first-line treatment of adult patients with HER2-positive unresectable or metastatic breast cancer. The designation was supported by data from the phase 3 DESTINY-Breast09 trial (NCT04784715). “This breakthrough therapy designation provides further recognition of the potential benefit of …
HER2 Breast Cancer: The Basics About This Specific Subtype
By: Shalmali Pal From: medpagetoday.com Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 (BRCA1/BRCA2opens in a new tab or window), and lifestyle factors is crucial for risk assessment. In general, the key types of breast canceropens in a new tab …
Novel ADC IBI354 Drives Responses in Pretreated HER2+ Advanced Breast Cancer
By: Chris Ryan From:.onclive.com Key Takeaways IBI354 showed a 59.1% overall response rate and 90.9% disease control rate in HER2-positive breast cancer patients. In the 9 mg/kg subgroup, the overall response rate was 72.4%, with a disease control rate of 89.7%. Treatment-emergent adverse effects occurred in 97.6% of patients, with 39.1% experiencing grade 3 or higher events. IBI354’s mechanism includes …